Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC
| العنوان: | Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC |
|---|---|
| المؤلفون: | Alexei Terman, Wilhelm Graf, Helgi Birgisson, Peter H Cashin, Johan Botling, Lana Ghanipour, Malin Enblad |
| المصدر: | Annals of Surgical Oncology. 27:293-300 |
| بيانات النشر: | Springer Science and Business Media LLC, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, endocrine system diseases, Clinical Laboratory Medicine, business.industry, Colorectal cancer, Kirurgi, medicine.disease, digestive system diseases, Klinisk laboratoriemedicin, 03 medical and health sciences, 0302 clinical medicine, Surgical oncology, 030220 oncology & carcinogenesis, Internal medicine, Medicine, Combined Modality Therapy, 030211 gastroenterology & hepatology, Surgery, In patient, business, neoplasms, Survival rate, Kras mutation |
| الوصف: | Background KRAS and BRAF mutations are prognostic and predictive tools in metastatic colorectal cancer, but little is known about their prognostic value in patients scheduled for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Therefore, we analyzed the prognostic impact of KRAS and BRAF mutations in patients with peritoneal metastases scheduled for CRS and HIPEC. Patients and Methods In a consecutive series of 399 patients scheduled for CRS and HIPEC between 2009 and 2017, 111 subjects with peritoneal metastases from primaries of the appendix, colon, or rectum were analyzed for KRAS mutation and 92 for BRAF mutation. Results Mutation in KRAS was present in 51/111 (46%), and mutated BRAF was found in 10/92 (11%). There was no difference in overall survival between KRAS mutation tumors and KRAS wild type, whereas BRAF mutation was associated with short survival. No subject with BRAF mutation survived 2 years. On multivariate analysis, completeness of cytoreduction score (CCS, p = 0.000001), presence of signet cell differentiation (p = 0.000001), and BRAF mutation (p = 0.0021) were linked with poor prognosis. Conclusions BRAF mutation is a marker of poor prognosis in patients with appendiceal and colorectal peritoneal metastases scheduled for CRS and HIPEC, whereas survival outcome in subjects with mutated KRAS does not differ from wild-type KRAS. This finding suggests that those with BRAF mutation should be considered for alternative treatment options. |
| وصف الملف: | application/pdf |
| تدمد: | 1534-4681 1068-9265 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d0069e7aa3b8c3d1f966c6397ff5f4c https://doi.org/10.1245/s10434-019-07452-2 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....0d0069e7aa3b8c3d1f966c6397ff5f4c |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 15344681 10689265 |
|---|